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Abstract
Objective In rare disease research, most randomized prospective clinical trials can only use limited number of patients 
and are comprised of highly heterogeneous populations. Therefore, it is crucial to report the results in such a manner that 
it allows for comparison of treatment effectiveness and biochemical control between studies. The aim of this review was to 
investigate the current methods that are being applied to measure and report growth hormone (GH) and insulin-like growth 
factor-1 (IGF-1) as markers for drug effectiveness in clinical acromegaly research.
Search strategy A systematic search of recent prospective and retrospective studies, published between 2012 and 2017, that 
studied the effects of somatostatin analogues or dopamine agonists in acromegaly patients was performed. The markers of 
interest were GH, IGF-1, and the suppression of GH after an oral glucose tolerance test (OGTT). Additionally, the use of 
pharmacokinetic (PK) measurements in these studies was analyzed. The sampling design, cut-off for biochemical control, 
reported units, and used summary statistics were summarized.
Results A total of 49 articles were selected out of the 263 screened abstracts. IGF-1 concentrations were measured in all 49 
studies, GH in 45 studies, and an OGTT was performed in 11 studies. A wide range of different cut-off values and sampling 
designs were used to determine biochemical control in acromegaly patients. The summary statistics were reported in various 
ways, with the percentage of biochemical control most frequently used. Nine studies sampled the PK at one or more time 
points. Non-compartmental analyses were commonly performed on the available PK data.
Conclusions The way GH and IGF-1 are measured and reported in acromegaly research varies considerably. A consensus 
on how to report study results would enable better comparisons between studies, thereby improving evidence based decision 
making to optimize treatment in acromegaly.
Keywords Acromegaly · Growth hormone · Pituitary adenoma · IGF-1—review
Introduction
Acromegaly is a rare disease (prevalence of 60–70 per mil-
lion [1]) characterized by growth hormone (GH) hypersecre-
tion that results in the abnormal growth of extremities, high 
morbidity, and an increased mortality risk. In virtually all Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1110 2-018-0884-4) contains 
supplementary material, which is available to authorized users.
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cases, acromegaly is the result of a GH secreting pituitary 
adenoma [2–4]. Under normal physiological conditions, 
GH is secreted in discrete bursts that result in a pulsatile 
plasma GH concentration–time profile. GH secretion is 
mainly upregulated by growth hormone-releasing hormone 
(GHRH), GH-releasing peptide (GHRP, e.g. ghrelin), and 
inhibited by somatostatin. Binding of GH to GH-receptors 
located in the liver induces insulin-like growth factor-1 
(IGF-I) synthesis and secretion into the circulation. Negative 
feedback on GH secretion is mediated by IGF-1 and by GH 
itself [5]. Major negative determinants of GH secretion are 
aging and adiposity, while on the other hand aromatizable 
sex steroids amplify GH secretion [6, 7].
Guideline recommendations
Both the GH and IGF-1 plasma concentrations are typically 
increased in active acromegaly and will decrease during 
effective treatment. Both biomarkers are therefore used in 
clinical practice to monitor biochemical control in acromeg-
aly and to determine treatment effectiveness. As a result of 
the biological mechanisms underlying acromegaly, the most 
recent guidelines, by the Endocrine Society and the Ameri-
can Association of Clinical Endocrinologists (AACE), for 
the diagnosis and treatment monitoring in acromegaly focus 
on three key biomarkers; (a) IGF-1, (b) (mean) GH and (c) 
level of suppression of GH concentrations during an oral 
glucose tolerance test (OGTT), further referred to in this 
article as the biomarkers of interest [8, 9].
Insulin-like growth factor-1
In clinical practice, a main treatment goal is a reduction 
in IGF-1 concentrations to the clinically accepted ‘normal’ 
values for age and sex, which has been associated with 
improved/normalized mortality. In the guidelines, the upper 
limit of normal (ULN) was introduced as a surrogate for 
‘safe’ IGF-1 levels which can be used to monitor the bio-
chemical control of an individual acromegaly patient. This 
ULN is commonly defined by 2 × the standard deviation 
(SD) of normal values, for age and sex, where age related 
changes have the largest impact on IGF-1 concentrations 
[10, 11]. Additionally, ULN corrected values have the added 
benefit that it can be used as a comparable measure of IGF-1 
concentrations between individuals.
Growth hormone
The primarily pathologically affected hormone in acro-
megaly is GH. A random GH measurement is therefore per-
formed to provide an indication of the actual endogenous 
24 h GH profile. However, the use of random GH levels, 
or the mean of multiple samples, to monitor treatment 
effectiveness has many challenges (e.g. highly pulsatile 
profile of GH, assay variability, lack of a safe range) but 
requires minimal clinical effort to obtain, compared to a full 
24 h GH profile with short sampling intervals which is not 
feasible in clinical practice. Therefore, IGF-1 is generally 
considered as a better and more stable biomarker. The 2014 
Endocrine Society guideline suggests the use of a random 
GH measurement (cut-off < 1 ng/ml), with only a low level 
of evidence for determining biochemical control [8]. Due to 
the challenges associated with random GH concentrations, 
the guidelines reports that these values should be handled 
with caution [8, 9]. For example, we have recently dem-
onstrated that a single random GH measurement underes-
timates the actual level of GH secretion in patients treated 
with somatostatin analogues [12].
Oral glucose tolerance test
An OGTT is performed as a test to differentiate between 
healthy individuals and patients with active acromegaly. 
Furthermore, an OGTT can be performed already 1 week 
after surgery to assess successful reduction of GH secretion 
[13]. In healthy individuals, the increase in plasma glucose 
levels suppresses GH secretion to well below 1 ng/ml [9]. 
Insufficient suppression of GH is indicative for disruption in 
the regulation of the hypothalamus–pituitary–somatotropic 
axis. A ‘standard’ OGTT is performed using 75 g of orally 
administered glucose and the monitoring of blood samples 
for GH concentrations every 30 min for 2 h. At present, the 
recommended cut-off used both for biochemical control, and 
the diagnosis of acromegaly, is a nadir GH of < 1 ng/ml 
[8], which has been re-adapted in 2014 from a previously 
more sensitive cut-off value of 0.4 ng/ml [9]. However, the 
quantification of GH concentrations in these lower regions 
is highly dependent on the used analytical assay.
Study comparison
There are limited prospective clinical trials that included 
large cohorts of acromegaly patients, due to the low preva-
lence of acromegaly. Therefore, systematic reviews and 
meta-analyses serve as a powerful tool to combine study 
results, thereby increasing statistical power [14]. For cor-
rect comparison of studies, the cut-off values used to deter-
mine biochemical control, and thereby the quantification of 
a response rate of a drug, should preferably be equal. As a 
complicating factor, the assays used to analyze serum GH 
and IGF-1 samples are heterogeneous and have been previ-
ously identified as important factors of influence [15]. Dif-
ferent international recombinant reference preparations have 
been used for the analysis of both hormones, which lead to 
discrepancies in the concentrations of the reported biomark-
ers between studies [15]. Additionally, the proposed cut-off 
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values reported in the guidelines are not assay specific which 
results in a bias in the interpretation of the proportion of 
patients with biochemical control between studies [15].
Pharmacokinetics
To establish the effectiveness of drug treatment in general, 
the investigated drug must reach the site of action, e.g. the 
pituitary for somatostatin analogues and dopamine agonists 
[16]. Sufficient circulating plasma/serum drug concentra-
tions should be reached and maintained in order to drive 
the desired drug effect at the level of the pituitary. These 
concentrations should be within the drug-specific thera-
peutic window in order to trigger an effect. Commonly, to 
assess the responsiveness of a patient to octreotide, which is 
a somatostatin analog, a suppression test is performed with 
a single dose. However, this test does not take into account 
the circulating plasma/serum concentrations that are reached 
and is perhaps not the most reliable predictor of drug effec-
tiveness [17]. Information on the pharmacokinetic (PK) 
profile of an individual patient can give additional informa-
tion on the level of inter-individual variability in response 
to a certain dose. This, in combination with the somatostatin 
subtype receptor expression of the target tissue could inform 
endocrinologists on the optimal treatment of patients [18].
Aim
The aim of this review is to summarize the methods that 
are being applied to measure and report GH and IGF-1 in 
studies that evaluated medical treatment efficacy in acromeg-
aly patients in peer-reviewed journals, published between 
2012 and 2017. It is assumed that this selection provides 
a good representation of the current state of the reporting 
of biomarkers, following the recommended cut-off values 
proposed in the 2011 guideline [9]. In addition, we made an 
overview of studies measuring the PK of the drugs of inter-
est and the performed PK analysis. Consequently, this will 
provide a perspective on the consistencies in the used meth-
odology and reporting of studies in acromegaly research and 
therewith in the comparability of study results.
Methods
In‑ and exclusion criteria
Prospective and retrospective clinical studies, that included a 
minimum of five acromegaly patients treated with the stand-
ard of treatment of somatostatin analogues (Octreotide, Lan-
reotide or Pasireotide) or dopamine agonists (Bromocriptine, 
Cabergoline), and investigated the effect of treatment on 
one or more biomarkers of interest were included. Studies 
solely investigating the effect of GH receptor antagonists 
were excluded, except when a GH receptor antagonist was 
studied as a separate cohort or in combination therapy with 
a somatostatin analog or dopamine agonist. Review articles, 
case studies, in vitro experiments and experiments in non-
human species were excluded.
Search strategies
Identification of relevant studies was done using the MED-
LINE database accessed through PubMed. Electronic search 
was performed on October 18th 2017. Studies which were 
indexed between January 2012 and October 2017, up until 
the search date, were included in this review. All included 
studies were therefore published after the release of the 
2011 guideline [9]. Sensitive search in PubMed was done 
using the search terms #1 to #5 presented below, where 
CompoundName was replaced by the expanded names of 
Bromocriptine, Cabergoline, Octreotide, Lanreotide and 
Pasireotide. The full search term can be found in the Online 
Resource 1. Search results were extracted from PubMed in 
plain text format.
#1(CompoundName [MeSH Terms/tiab])
#2 AND (Acromegaly [MeSH Terms] OR Acromegaly 
[tiab] OR Somatotropinoma [tiab] OR pituitary adenoma 
[MeSH Terms] OR pituitary adenoma [tiab])
#3 NOT Prolactinoma [tiab]
#4 NOT (Review [Publication Type] OR Case reports 
[Publication Type])
#5 AND (“2012/01/01″[Date - Publication] : 
“2018″[Date - Publication])
Study selection and data extraction
All studies were screened on title, abstract, and key-
words. For selected studies, full text articles were studied 
and checked against the in- and exclusion criteria. For all 
included full text articles, study characteristics were summa-
rized in a data extraction form. This form consisted of gen-
eral study characteristics, information on the study design, 
the used biomarkers, analytical assay, and the reported sum-
mary statistics. An overview of all variables documented in 
this data extraction form can be found in Online Resource 2.
Results
A total of 49 studies fulfilled all in- and exclusion criteria 
(Fig. 1). The selected articles cover a wide range of study 
designs, from randomized phase I clinical trials to post-
marketing approval retrospective database analyses. The 
majority of articles reported on prospective trials (63%). In 
total, the studies report on data of more than 6400 patients. 
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The median number of subjects that completed a study was 
58, with a 25–75% interquartile range [IQR] from 27 to 
107. One article included a large number of patients: 2572 
patients from the United Kingdom that were included in a 
retrospective database analysis [19]. The patient populations 
in the studies were diverse, varying from treatment naïve to 
long term somatostatin treatment after surgery. An extensive 
overview of the used study designs and the patient popula-
tions per study has been included in Online Resource 3.
The IGF-1 concentrations were measured in all 49 stud-
ies (Table 1), GH was measured in 45 studies (Table 2), and 
an OGTT was performed in 11 studies (Table 3). The tables 
present a summary of the reporting of the sampling design, 
used cut-offs, used summary statistics and the frequency of 
reporting the analytical assay for each biomarker. Approxi-
mately 92% of the studies reported both the IGF-1 and the 
GH response in the population. One article was excluded 
from the summary tables due to the reporting of a population 
pharmacokinetic/pharmacodynamic (PK/PD) model instead 
of focusing on the biochemical control in the population, 
which will therefore be reported in the “Pharmacokinetics” 
section [20]. Only nine studies measured and reported the 
PK of the drug of interest (Table 4).
Insulin‑like growth factor‑1
The majority of studies that reported IGF-1 outcomes 
included one fasting or one/two random sample(s) for the 
assessment of the IGF-1 concentrations (54%), others did 
not report the sampling design. IGF-1 was reported as ULN 
corrected levels in 60%, and in concentration units (ng/ml) 
in 44% of the studies. The reporting of both ULN corrected 
levels and IGF-1 concentrations also occurred. The ULN 
corrected cut-off used to assess individual biochemical con-
trol, ranged from < 1.0x ULN to < 1.5x ULN. The used sum-
mary statistics to report the IGF-1 concentrations ranged 
from individual profiles, geometric means with confidence 
intervals, % change from baseline, to time of nadir IGF-1 
concentrations. The % biochemical control, individual ULN 
corrected levels and mean ± SD were most commonly used. 
A total of 22 other ways of reporting the IGF-1 concentra-
tions were identified and 83% of the studies reported the 
used IGF-1 assay.
Growth hormone
A wide variability was observed in the sampling schedule 
used to measure GH, ranging from 1 random sample to the 
mean of 8–10 samples taken with 1 h intervals. A total of 
10 studies used a random 1 point sample whereas 14 studies 
did not report the number and the timing of samples taken. 
The most commonly used GH cut-offs were < 1 ng/ml and 
< 2.5 ng/ml, used in 36 and 70% of studies respectively, indi-
cating that multiple cut-offs were reported in an individual 
study. In the 44 studies reporting GH results, 25 different 
ways were used to report the GH summary statistics, with 
the % biochemical control, individual concentrations and 
mean ± SD as most prevalent outcomes. A total of 34 out of 
45 studies reported the used GH assay.
Oral glucose tolerance test
Four studies reported the execution of an OGTT in their 
methods section but did not report any results, these studies 
Fig. 1  Flow diagram of included studies and main reasons for exclusion. N total number, n subset of total, OGTT oral glucose tolerance test, GH 
growth hormone, IGF-1 insulin-like growth factor 1, PK pharmacokinetics
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Table 1  Overview of the methods, cut-off and statistical reporting of insulin-like growth factor 1 observations (n = 48), ordered by frequency
SD-Score Standard deviation score, ULN upper limit of normal, CI confidence interval, SD standard deviation, IQR interquartile range, SEM 
standard error of mean, SE standard error
IGF-1 analysis Number of studies (%) References
Method
 1 Fasting sample 13 (27%) [21–33]
 1 Sample 12 (25%) [34–45]
 Mean of 2 samples (30 min and 1 min before drug 
administration)
1 (2%) [46]
 Not reported 22 (46%) [19, 47–67]
Reported units
 ULN corrected 29 (60%) [21–28, 30–32, 34, 37–39, 41–43, 45, 48–50, 52–55, 59, 65, 66]
 ng/ml 21 (44%) [21, 22, 29, 33, 35, 36, 40, 44, 46, 47, 49, 51, 56, 58–60, 63–67]
 SD-score 2 (4%) [44, 63]
 ng/dl 1 (2%) [31]
 nmol/L 1 (2%) [57]
 Not reported 3 (6%) [19, 61, 62]
IGF-1 cut-off for biochemical control
 < ULN 41 (85%) [22–27, 29, 31, 33–44, 46–67]
 < 1.2x ULN 6 (13%) [21, 28, 30, 36, 45, 54]
 < 1.3x ULN 2 (4%) [31, 34]
 < 1.1x ULN 1 (2%) [32]
 < 1.5x ULN 1 (2%) [26]
 > 20% decrease from baseline 1 (2%) [21]
 > 50% decrease from baseline 1 (2%) [28]
 No cut-off reported/used 1 (2%) [19]
Summary statistics
 % Biochemical control 41 (85%) [19, 21–31, 33–35, 39, 41–48, 50–63, 65–67]
 Mean ± SD 20 (42%) [23, 24, 26, 29, 33–35, 38, 39, 41, 42, 44, 46, 48, 54, 55, 57, 63, 66, 67]
 Individual ULN corrected levels 17 (35%) [21, 24–26, 30–32, 37, 38, 41, 44, 45, 48, 53, 54, 63, 65]
 % Change mean ± SD 10 (21%) [22, 24, 30, 35, 46, 48, 57, 63, 65, 67]
 Median (range) 10 (21%) [31, 37, 42, 48, 51–54, 57, 64]
 Median (IQR) 9 (19%) [21, 24, 28, 29, 34, 45, 48, 49, 59]
 % Biochemical control [95% CI]
no method reported
8 (17%) [23, 34, 36, 39, 42–44, 46]
 Mean ± SD [range] 5 (10%) [30, 47, 54, 60, 65]
 Mean ± SE 5 (10%) [22, 29, 36, 43, 55]
 % Change individual concentrations 4 (8%) [21, 31, 53, 65]
 Mean 4 (8%) [31, 39, 43, 47]
 % Change median 3 (6%) [22, 37, 64]
 % Change median [range] 3 (6%) [37, 52, 57]
 % Change median [IQR] 3 (6%) [32, 40, 49]
 Individual IGF-1 concentrations 3 (6%) [31, 56, 66]
 % Change mean 2 (4%) [29, 39]
 % Change mean [95% CI] 2 (4%) [29, 41]
 Geometric mean [95% CI] 2 (4%) [40, 41]
 % Biochemical control [90% exact CI]
 Clopper-Pearson exact 2-sided 90% CI
1 (2%) [37]
 % Change mean ± SD [Range] 1 (2%) [65]
 % Change mean [SEM] 1 (2%) [23]
 Geometric mean [68% CI] 1 (2%) [40]
 Mean ± SE [range] 1 (2%) [58]
 Median 1 (2%) [42]
 Time to nadir IGF-1 (mean ± SD) 1 (2%) [65]
IGF-1 hormone assay reported
 Yes (%) 40 (83%) [19, 21, 23–36, 38, 40–46, 49, 52–61, 63–67]
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Table 2  Overview of the methods, cut-off and statistical reporting for growth hormone (n = 44), ordered by frequency
GH analysis Number of studies References
Method
 1 Random sample 10 (23%) [21, 22, 35, 36, 45, 49, 50, 55, 59, 63]
 1 Fasting sample 8 (18%) [25, 26, 28, 30, 31, 48, 62, 67]
 Mean of 5 samples (2 h period) 8 (18%) [34, 35, 37, 39–43]
 Mean of 2/3 fasting samples (15–30 min interval) 1 (2%) [31]
 Mean of 3 fasting samples (1 h interval) 1 (2%) [23]
 Mean of 4 samples (30 min interval) 1 (2%) [46]
 Mean of 4 samples (1 h interval) 1 (2%) [44]
 Mean of 4 samples (4 h interval) 1 (2%) [48]
 Mean of 5 samples (10–15 min interval) 1 (2%) [29]
 Mean of 6 samples (2.5 h period) 1 (2%) [22]
 Mean of 8–10 samples (1 h interval) 1 (2%) [32]
 Not reported 14 (32%) [19, 38, 47, 51–54, 56–58, 60, 64–66]
GH cut-off for biochemical control
 < 2.5 ng/ml 31 (70%) [22, 23, 26, 28–30, 32, 34–37, 39–44, 46–51, 53, 56–58, 60, 62, 
64, 67]
 < 1 ng/ml 16 (36%) [21, 23, 25, 28, 29, 32, 34, 36, 44, 48, 50, 51, 53, 57, 59, 62]
 > 20% decrease from baseline 2 (5%) [21, 36]
 < 1.5 ng/ml 1 (2%) [45]
 < 2 ng/ml 1 (2%) [19]
 < 5 ng/ml 1 (2%) [19]
 > 50% decrease from baseline 1 (2%) [44]
 No cut-off reported/used 8 (18%) [31, 38, 52, 54, 55, 63, 65, 66]
Summary statistics
 % Biochemical control 31 (70%) [19, 21–23, 25, 26, 28, 29, 32, 34, 35, 39, 41–51, 53, 56–60, 62, 
67]
 Mean ± SD 18 (41%) [23, 29, 34, 35, 39, 41, 42, 44, 46, 48, 54, 55, 57, 62, 63, 65–67]
 Individual concentrations 13 (30%) [25, 30–32, 37, 38, 41, 44, 45, 48, 54, 56, 63]
 Median (IQR) 10 (23%) [21, 28, 29, 34, 45, 48, 49, 51, 53, 59]
 % Biochemical control [95% CI] (no method reported) 8 (18%) [23, 34, 36, 39, 42–44, 46]
 % Change from baseline mean + SD 7 (16%) [22, 35, 46, 48, 57, 63, 67]
 Median [range] 7 (16%) [37, 42, 48, 52, 54, 57, 64]
 Mean 4 (9%) [19, 39, 43, 47]
 Mean ± SD [range] 4 (9%) [30, 47, 54, 60]
 % Change from baseline median 3 (7%) [22, 37, 64]
 % Change from baseline median [range] 3 (7%) [37, 51, 57]
 % Change from baseline median (IQR) 3 (7%) [32, 40, 49]
 Mean ± SE 3 (7%) [29, 36, 43]
 % Change from baseline mean 2 (5%) [29, 39]
 % Change from baseline mean (95% CI) 2 (5%) [29, 41]
 Geometric mean [95% CI] 2 (5%) [40, 41]
 Mean [range] 2 (5%) [25, 58]
 Range 2 (5%) [31, 35]
 % Biochemical control [90% exact CI]
(Clopper-Pearson exact 2-sided 90% CI)
1 (2%) [37]
 % Change from baseline individual 1 (2%) [31]
 % Change from baseline mean [range] 1 (2%) [31]
 Geometric mean [68% CI] 1 (2%) [40]
 Maximum observed GH concentration 1 (2%) [26]
 Median 1 (2%) [42]
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were therefore excluded from the summary table [19, 34, 
35, 47]. In the majority of the included studies, the used 
methodology for an OGTT was not reported (8 out of 11). 
For the studies that did report the methodology, different 
sampling schedules were used, although all did use a glucose 
loading of 75 g. The interpretation of the outcomes of the 
OGTT varied between studies, with cut-offs for GH ranging 
from 0.4 ng/ml to 1 µg/dl. The majority of studies (n = 6) 
did not use the OGTT results in determining the biochemi-
cal control of a patient and only reported summary statistics 
or individual GH concentrations. The used GH assay was 
reported in 7 out of 11 studies.
Pharmacokinetics
A total of 9 studies took samples for PK analysis of the 
drug of interest. The data were analyzed using a non-
compartmental analysis in all but one article that applied 
a population PK/PD model [20]. Due to the wide range in 
the number of samples taken in each study, different ways 
of reporting were used. Most commonly, the graphical 
Table 2  (continued)
GH analysis Number of studies References
 Proportion above 40 ng/ml 1 (2%) [26]
Growth hormone assay reported
 Yes (%) 34 (77%) [19, 21, 23, 25, 26, 28–32, 34–36, 40–46, 48, 49, 52–54, 56–60, 
63, 64, 66, 67]
CI Confidence interval, SD standard deviation, IQR interquartile range, SE standard error
Table 3  Overview of the 
methods, cut-off and statistical 
reporting for the oral glucose 
tolerance test (n = 11), ordered 
by frequency
SD Standard deviation, IQR interquartile range




 2 h period: pre-dose, 30, 60, 120 min 1 (9%) [24]
 2 h period: 30, 60, 90, 120 min 1 (9%) [45]
 3 h period: pre-dose, 30, 60, 90, 120, 180 min 1 (9%) [33]
 Not reported 8 (73%) [27, 30, 38, 59, 61–63, 67]
Glucose administration
 75 g 5 (45%) [24, 27, 33, 45, 59]
 Not defined 6 (55%) [30, 38, 61–63, 67]
Nadir cut-off for biochemical control
 < 1 ng/ml 5 (45%) [24, 33, 59, 62, 67]
 < 0.4 ng/ml 1 (9%) [67]
 < 1 µg/dl 1 (9%) [61]
 < 2 mU/L 1 (9%) [27]
 No cut-off reported/used 4 (36%) [30, 38, 45, 63]
Summary statistics
 % Biochemical control 5 (45%) [24, 27, 33, 61, 62, 67]
 Individual levels 3 (27%) [24, 30, 38]
 Mean ± SD 3 (27%) [24, 33, 63]
 Median (IQR) 3 (27%) [24, 45, 59]
 % Nadir change from baseline mean ± SD 1 (9%) [24]
 Mean ± SD [range] 1 (9%) [30]
 Mean ± SD pre-glucose GH 1 (9%) [24]
 Median 1 (9%) [62]
 Median (IQR) pre-glucose GH 1 (9%) [24]
Growth hormone assay reported
 Yes (%) 7 (64%) [30, 33, 45, 59, 61, 63, 67]
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analysis was presented as mean ± standard error (SE) 
over time. The correlation of an individual’s PK with their 
response on GH or IGF-1, was only reported in 2 studies.
Discussion
This review clearly demonstrates that many methods are 
applied to measure and report on biomarkers in acro-
megaly research. To improve comparability of results 
between studies and the determination of optimal treat-
ment in acromegaly, protocols should be more uniform 
on the biochemical reporting. However, different cut-off 
values and summary statistics are commonly applied to 
determine when a patient qualifies as being biochemically 
controlled, limiting the possibility to include the study 
results in a meta-analysis.
Insulin‑like growth factor‑1
To assess if IGF-1 concentrations decrease to ‘safe’ ranges 
after treatment, the use of ULN corrected levels should be 
used as a surrogate for treatment effectiveness. Additionally, 
the influence of age and sex on IGF-1 concentrations needs 
to be corrected for to enable comparison within a population 
and between studies. Unless the study population charac-
teristics are similar (small age range, same sex) the report-
ing of IGF-1 concentrations that are not adjusted for by age 
and sex adds limited value. However, we observed that 40% 
of the studies reported IGF-1 concentrations that were not 
adjusted by the ULN, precluding reliable comparisons of 
biochemical control between studies. The healthy population 
that is used as reference to determine normal IGF-1 concen-
trations over age and sex may also play a role, however it 
is hypothesized that differences in large reference popula-
tions are small. Also, many of the studies (46%) did not 
clearly report the number of samples taken to measure the 
IGF-1 concentrations. However, since the serum IGF-1 con-
centration is assumed to be relatively stable during the day, 
this will most likely have a limited effect on the outcome 
[68]. The response to drug treatment can also be judged on 
whether the IGF-1 reduction is consistent on multiple occa-
sions during treatment, to assess the day-to-day variability. 
This approach, using longitudinal IGF-1 data, would require 
validation compared to the use of a single IGF-1 sample 
which are being measured at a fixed time period after the 
start of treatment.
The variability in cut-offs that are currently used to 
determine biochemical control was also identified by Stalla 
et al. [69]. They identified that 32% of the respondents of 
an online survey from 45 countries apply a cut-off of 1.3x 
ULN and 18% use a cut-off of 1.5x ULN. The results of 
this study are in line with the used cut-off values identified 
in this review, with 13% of the studies accepting ULN cor-
rected IGF-1 levels to be < 1.2x ULN, whereas one study 
used a cut-off of 1.5x ULN.
The high proportion of studies (85%) reporting bio-
chemical control can only be used for the comparison 
between studies, if identical criteria to assess biochemi-
cal control are used. However, a total of seven different 
cut-offs to determine biochemical control were used. The 
impact of the approach to determine biochemical control 
is high, which was exemplified by the use of time weighted 
averages for IGF-1 compared to the use of only a single 
measurement at the end of treatment, resulting in different 
outcomes [70]. The majority of studies (83%) reported the 
used IGF-1 assay. This reporting is especially important 
when non-corrected IGF-1 concentrations are reported. 
For the correct reporting of IGF-1 outcomes, the used 
method of sampling, the criteria for biochemical control 
(preferably < 1x ULN), and the % of change from base-
line per individual should be presented. If non-corrected 
IGF-1 concentrations are given, the individual’s age and 
sex should also be included.
Growth hormone
The wide range of methods to sample GH and determine 
biochemical control of GH can influence the results, as was 
recently shown in a paper that suggested that in patients 
with active acromegaly, the mean of four samples, sampled 
with 4 h intervals, reflected an endogenous 24 h GH profile 
best [12]. Only one trial included in this review used this 
approach to determine the mean GH level, indicating that 
this sampling method is rarely used in clinical practice [48].
In 70% of the studies, both the GH and IGF-1 concentra-
tion were used to define the individual biochemical control, 
with a multitude of different cut-off values. This percentage 
is high when taking into account the cautionary remarks 
in the guidelines on the use of GH levels to determine bio-
chemical control and the lack of a safe reference range. The 
wide use of < 1 ng/ml or < 2.5 ng/ml as cut-off value for 
adequate control of GH precludes reliable comparability of 
studies. The reporting of the percentage biochemical con-
trol using both cut-offs would improve this. For GH report-
ing, only 77% of the studies specified which GH assay was 
used. This percentage is low, considering the high variability 
between assays, and should be made mandatory for all future 
publications. If more than 1 GH assay was used in a study, 
between or within patients, it should also be noted whether 
the same international reference was used or what correction 
to the data was applied [19]. The method of sampling, the 
used analytical assay, the distribution of GH concentrations 
and the % of change from baseline are informative to include 
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in a report. Preferably, the GH observations should not be 
used to assess the biochemical control and treatment effec-
tiveness, due to the reasons previously discussed.
Oral glucose tolerance test
The OGTT is commonly performed at study initiation for 
the confirmation of active acromegaly or to assess surgery 
success multiple weeks after surgery. Unfortunately, there 
is limited use in performing an OGTT to determine medical 
treatment efficacy. However, the GH nadir concentrations 
that are obtained as the main outcome of an OGTT at study 
initiation or after surgery reflects an individual’s disease 
state, which may be a predictor of an individual’s response 
to treatment. Therefore, a consensus in the reporting of the 
OGTT results would be appropriate to allow comparison 
between the responses in different biomarkers. The analysis 
of the OGTT show that different cut-offs were used for the 
GH response after an OGTT in which biochemical control 
was most commonly defined as a GH nadir < 1 ng/ml, which 
is supported by the Endocrine Society guidelines [8]. Only 
one study performed and reported the sampling schedule as 
suggested in literature, a 2 h sampling period with samples 
every 30 min. The majority (64%) of studies provided suffi-
cient details on the used GH assay. Since GH concentrations 
are measured in the lower assay regions during an OGTT, 
inclusion of the details of the GH assay used in the methods 
section is imperative.
Pharmacokinetics
In this review, nine studies (18% of total) were available that 
measured at least 1 PK sample. When these studies were 
explored, all except one study [20], performed a standard 
non-compartmental analysis. A non-compartment analysis 
will generally result in the reporting of summary statistics 
of the secondary PK parameters  (Cmax,  tmax, area under the 
curve) [71]. Alternatively, individual PK profiles are more 
informative than these summary statistics. This was also 
the case when the dosage and dose frequency was altered 
for Lanreotide Autogel [21]. In this case, the individual PK 
profiles showed a clear overlap between the two cohorts 
and a high variability within the groups. This could indicate 
that the variability in drug exposure between individuals is 
higher than the exposure differences caused by the alterna-
tive dosing regimen.
Despite the importance of individualizing treatment 
responses, the current focus in literature is predominantly 
on the identification of a dose–response relationship, which 
neglects the individual concentrations that are reached in 
patients. In the investigated studies, the reporting of the 
time after dose was inconsistent. This may have a signifi-
cant impact on the observed response, which is depended 
on the drug concentrations at that time point, and should be 
included in the reporting.
The discrepancy in drug dose and response between indi-
viduals might be caused by the high variability in individual 
serum/plasma drug concentrations. This high variability is 
often misrepresented due to the reporting of the mean ± SE 
in PK profiles [22, 34, 36]. Especially in large populations, 
the use of standard errors are a poor indicator to assess the 
level of inter-individual variability [72]. This can be clearly 
observed in the study by Chieffo et al. [36] in which individ-
ual concentrations reached 33 times the mean  Cmax, which 
cannot be clearly observed from the reported figure. In this 
situation, the use of individual profiles, or a 95% confidence 
interval, is much more informative to quantify and show the 
inter-individual variability in the PK over time. Besides the 
variability in response to treatment due to tumor heterogene-
ity, the impact of different levels of circulating drug levels 
are commonly ignored.
The studies that measured the PK of the drug had the 
unique opportunity to investigate the concentration-effect 
relationship and explore possible covariates, variables that 
could explain the inter-individual variability in the PK, 
while studying a wide range of concentrations in a highly 
heterogeneous population. This approach was only under-
taken by Garrido et al. [20] in the development of a popula-
tion pharmacodynamic model that included drug response 
on both the individual mean GH and IGF-1 levels, allowing 
a more evidence based approach in acromegaly treatment.
Summary statistics
The most common way of reporting the biomarkers concen-
trations in the included studies was a mean ± SD, which was 
reported in 42% of the IGF-1 studies and in 41% of the GH 
studies. However, as a general rule of thumb, the mean ± SD 
should only be used for normally distributed data [73]. That 
GH data is commonly non-normally distributed can be 
clearly observed from the report by Neggers et al., where the 
depicted standard deviation would indicate that more than 
15% of the data are negative GH concentrations [23]. Many 
tests for data normality exist (e.g. Shapiro–Wilk, Kolmogo-
rov–Smirnov), which are commonly included in statistical 
software, and are required to be checked as an assumption 
for some statistical tests [74]. For non-normally distributed 
data, the reporting of a median and IQR (25–75% distribu-
tion of the data) is advised [73]. If data are non-normally 
distributed, a Mann–Whitney U test can be applied to assess 
significant differences between groups. Online Resource 4 
contains an extensive checklist of the advised reporting of 
IGF-1, GH, OGTT and PK results in acromegaly studies.
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Study inclusion criteria
In addition to the variability in the reported outcomes, a 
wide variability in the study inclusion criteria was identified 
(Online Resource 3). This patient selection criteria differed 
between studies on the basis of both the used GH and IGF-1 
cut-offs or medical treatment history (e.g. treatment naïve, 
long term treatment), which may significantly alter the study 
outcomes. However, the impact of patient selection, and the 
identification of possible differences between patient groups, 
cannot yet be quantified due to the differences in the meth-
ods used to measure and report GH and IGF-1, as identified 
in this review.
In conclusion, supplementary to a consensus on the diag-
nosis and the monitoring of treatment effectiveness in acro-
megaly, a second consensus on reporting of the results of 
both prospective and retrospective trials is urgently needed. 
This uniform reporting should, as a minimum, include the 
patient inclusion and exclusion criteria, the definition of bio-
chemical control used in a study, the proportion of patients 
achieving biochemical control after treatment (IGF-1 and/
or GH), the percentage of change from baseline, the ULN-
corrected levels for IGF-1 concentrations (mean/median 
depending on data normality), the used sampling design, and 
preferably, individual results. When GH concentrations are 
reported, the used analytical assay must be included, with 
the international reference standard. Additionally, the results 
of an OGTT or the individual PK profiles can be used to 
obtain explanatory information on an individual’s response 
to a drug which can be used as a basis for dose optimiza-
tion. These recommendations will enhance the inter-study 
comparison and therewith improve evidence based decision 
making in acromegaly.
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